Madrigal Pharmaceuticals (MDGL) — insider trading
Health Care · NASDAQ
Madrigal Pharmaceuticals (MDGL) has 84 reported SEC Form 4 insider transactions in our data, including 62 open-market sales among the most recent 84 (latest 2026-09-11).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 120 | $546.38 | $65.6K | Form 4 |
| 2026-09-11 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 761 | $544.83 | $414.6K | Form 4 |
| 2026-09-11 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 1,539 | $544.02 | $837.3K | Form 4 |
| 2026-09-11 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 1,202 | $542.60 | $652.2K | Form 4 |
| 2026-09-11 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 368 | $541.64 | $199.3K | Form 4 |
| 2026-09-11 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 687 | $540.59 | $371.4K | Form 4 |
| 2026-09-11 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 160 | $537.62 | $86.0K | Form 4 |
| 2026-09-11 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 218 | $535.94 | $116.8K | Form 4 |
| 2026-09-11 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 106 | $534.06 | $56.6K | Form 4 |
| 2026-09-11 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 60 | $533.09 | $32.0K | Form 4 |
| 2026-09-09 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 160 | $542.55 | $86.8K | Form 4 |
| 2026-09-09 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 362 | $541.65 | $196.1K | Form 4 |
| 2026-09-09 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 505 | $540.19 | $272.8K | Form 4 |
| 2026-09-09 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 215 | $539.03 | $115.9K | Form 4 |
| 2026-09-09 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 520 | $538.30 | $279.9K | Form 4 |
| 2026-09-09 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 640 | $537.17 | $343.8K | Form 4 |
| 2026-09-09 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 1,040 | $536.11 | $557.6K | Form 4 |
| 2026-09-09 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 644 | $535.27 | $344.7K | Form 4 |
| 2026-09-09 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 396 | $534.20 | $211.5K | Form 4 |
| 2026-09-09 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 512 | $533.09 | $272.9K | Form 4 |
| 2026-09-09 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 368 | $531.99 | $195.8K | Form 4 |
| 2026-09-09 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 522 | $530.23 | $276.8K | Form 4 |
| 2026-09-09 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 347 | $529.27 | $183.7K | Form 4 |
| 2026-09-09 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 131 | $527.88 | $69.2K | Form 4 |
| 2026-08-17 | Kelley Shannon T | Officer (General Counsel) | Open-market sale | 664 | $514.97 | $341.9K | Form 4 |
| 2026-08-15 | REED JOHN C | Director | Grant / award / vesting (derivative) | 1,078 | — | $0 | Form 4 |
| 2026-08-15 | REED JOHN C | Director | Grant / award / vesting | 647 | — | $0 | Form 4 |
| 2026-07-20 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 280 | $555.05 | $155.4K | Form 4 |
| 2026-07-20 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 1 | $550.72 | $551 | Form 4 |
| 2026-07-20 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 153 | $550.01 | $84.2K | Form 4 |
| 2026-07-20 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 47 | $548.87 | $25.8K | Form 4 |
| 2026-07-20 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 680 | $547.70 | $372.4K | Form 4 |
| 2026-07-20 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 269 | $547.08 | $147.2K | Form 4 |
| 2026-07-20 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 275 | $545.71 | $150.1K | Form 4 |
| 2026-07-20 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 545 | $544.71 | $296.9K | Form 4 |
| 2026-07-20 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 110 | $543.79 | $59.8K | Form 4 |
| 2026-07-20 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 140 | $542.75 | $76.0K | Form 4 |
| 2026-07-17 | Sibold William John | Director, Officer (President and CEO) | Option exercise / conversion (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-07-17 | Sibold William John | Director, Officer (President and CEO) | Option exercise / conversion | 50,000 | — | — | Form 4 |
| 2026-06-17 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director | Grant / award / vesting (derivative) | 1,532 | — | $0 | Form 4 |
| 2026-06-17 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director | Grant / award / vesting (derivative) | 1,532 | — | $0 | Form 4 |
| 2026-06-17 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director | Grant / award / vesting | 908 | — | $0 | Form 4 |
| 2026-06-17 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director | Grant / award / vesting | 908 | — | $0 | Form 4 |
| 2026-06-17 | Brennan Daniel J. | Director | Grant / award / vesting (derivative) | 681 | — | $0 | Form 4 |
| 2026-06-17 | Brennan Daniel J. | Director | Grant / award / vesting | 404 | — | $0 | Form 4 |
| 2026-06-17 | Daly James M | Director | Grant / award / vesting (derivative) | 766 | — | $0 | Form 4 |
| 2026-06-17 | Daly James M | Director | Grant / award / vesting | 454 | — | $0 | Form 4 |
| 2026-06-17 | FOUSE JACQUALYN A | Director | Grant / award / vesting (derivative) | 766 | — | $0 | Form 4 |
| 2026-06-17 | FOUSE JACQUALYN A | Director | Grant / award / vesting | 454 | — | $0 | Form 4 |
| 2026-06-17 | Levy Richard S | Director | Grant / award / vesting (derivative) | 766 | — | $0 | Form 4 |
| 2026-06-17 | Levy Richard S | Director | Grant / award / vesting | 454 | — | $0 | Form 4 |
| 2026-06-17 | Taub Rebecca | Director | Grant / award / vesting (derivative) | 766 | — | $0 | Form 4 |
| 2026-06-17 | Taub Rebecca | Director | Grant / award / vesting | 454 | — | $0 | Form 4 |
| 2026-06-01 | Soergel David | Officer (Chief Medical Officer) | Open-market sale | 1,042 | $495.74 | $516.6K | Form 4 |
| 2026-05-22 | Levy Richard S | Director | Open-market sale | 80 | $519.98 | $41.6K | Form 4 |
| 2026-05-22 | Levy Richard S | Director | Open-market sale | 782 | $518.76 | $405.7K | Form 4 |
| 2026-05-22 | Levy Richard S | Director | Open-market sale | 1,497 | $517.59 | $774.8K | Form 4 |
| 2026-05-22 | Levy Richard S | Director | Open-market sale | 723 | $516.87 | $373.7K | Form 4 |
| 2026-05-22 | Levy Richard S | Director | Open-market sale | 657 | $515.92 | $339.0K | Form 4 |
| 2026-05-22 | Levy Richard S | Director | Open-market sale | 343 | $514.67 | $176.5K | Form 4 |
| 2026-05-22 | Levy Richard S | Director | Open-market sale | 40 | $512.97 | $20.5K | Form 4 |
| 2026-05-22 | Levy Richard S | Director | Open-market sale | 439 | $512.50 | $225.0K | Form 4 |
| 2026-05-22 | Levy Richard S | Director | Open-market sale | 610 | $511.40 | $312.0K | Form 4 |
| 2026-05-22 | Levy Richard S | Director | Open-market sale | 151 | $510.36 | $77.1K | Form 4 |
| 2026-05-22 | Levy Richard S | Director | Open-market sale | 320 | $508.24 | $162.6K | Form 4 |
| 2026-05-22 | Levy Richard S | Director | Open-market sale | 40 | $506.68 | $20.3K | Form 4 |
| 2026-05-18 | Soergel David | Officer (Chief Medical Officer) | Open-market sale | 844 | $515.90 | $435.4K | Form 4 |
| 2026-03-06 | Sibold William John | Director, Officer (President and CEO) | Open-market sale | 1,663 | $431.94 | $718.3K | Form 4 |
| 2026-03-06 | Dier Mardi | Officer (EVP and CFO) | Open-market sale | 40 | $437.65 | $17.5K | Form 4 |
| 2026-03-06 | Dier Mardi | Officer (EVP and CFO) | Open-market sale | 80 | $436.69 | $34.9K | Form 4 |
| 2026-03-06 | Dier Mardi | Officer (EVP and CFO) | Open-market sale | 80 | $435.32 | $34.8K | Form 4 |
| 2026-03-06 | Dier Mardi | Officer (EVP and CFO) | Open-market sale | 160 | $434.20 | $69.5K | Form 4 |
| 2026-03-06 | Dier Mardi | Officer (EVP and CFO) | Open-market sale | 116 | $432.56 | $50.2K | Form 4 |
| 2026-03-06 | Dier Mardi | Officer (EVP and CFO) | Open-market sale | 120 | $430.90 | $51.7K | Form 4 |
| 2026-03-06 | Dier Mardi | Officer (EVP and CFO) | Open-market sale | 40 | $429.58 | $17.2K | Form 4 |
| 2026-03-06 | Dier Mardi | Officer (EVP and CFO) | Open-market sale | 160 | $429.00 | $68.6K | Form 4 |
| 2026-03-06 | Dier Mardi | Officer (EVP and CFO) | Open-market sale | 80 | $427.85 | $34.2K | Form 4 |
| 2026-03-06 | Dier Mardi | Officer (EVP and CFO) | Open-market sale | 420 | $426.86 | $179.3K | Form 4 |
| 2026-03-06 | Dier Mardi | Officer (EVP and CFO) | Open-market sale | 40 | $425.08 | $17.0K | Form 4 |
| 2026-03-06 | Dier Mardi | Officer (EVP and CFO) | Open-market sale | 646 | $431.94 | $279.0K | Form 4 |
| 2026-03-04 | Sibold William John | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 18,743 | — | $0 | Form 4 |
| 2026-03-04 | Sibold William John | Director, Officer (President and CEO) | Grant / award / vesting | 14,995 | — | $0 | Form 4 |
| 2026-03-04 | Dier Mardi | Officer (EVP and CFO) | Grant / award / vesting (derivative) | 6,519 | — | $0 | Form 4 |
| 2026-03-04 | Dier Mardi | Officer (EVP and CFO) | Grant / award / vesting | 5,215 | — | $0 | Form 4 |
Ask the chat about MDGL's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Madrigal Pharmaceuticals (MDGL).
Last updated 2026-09-11 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.